


Daidzein

Cat. No.:	HY-N0019
CAS No.:	486-66-8
Molecular Formula:	C ₁₅ H ₁₀ O ₄
Molecular Weight:	254.24
Target:	PPAR; Endogenous Metabolite
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Storage:	4°C, stored under nitrogen * In solvent : -80°C, 1 year; -20°C, 6 months (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (196.66 mM)
 H₂O : < 0.1 mg/mL (ultrasonic) (insoluble)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.9333 mL	19.6665 mL	39.3329 mL
	5 mM	0.7867 mL	3.9333 mL	7.8666 mL
	10 mM	0.3933 mL	1.9666 mL	3.9333 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 20 mg/mL (78.67 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Daidzein is a soy isoflavone, which acts as a PPAR activator.

IC₅₀ & Target

PPAR-α

PPAR-γ

In Vitro

In 3T3-L1 adipocytes, Daidzein inverses the attenuation of adiponectin gene expression by co-culture, and these effects are inhibited by the PPAR-γ specific inhibitor. Daidzein attenuates the reduction of adiponectin expression in adipocytes, and a

PPAR- γ specific inhibitor abrogated this effect. Direct activation of PPAR- α and- γ by Daidzein is confirmed by a luciferase reporter assay. In HEK293T cells, Daidzein significantly increases PPAR- α transcriptional activity in a concentration-dependent manner. Although an obvious dose-dependency is not observed in PPAR- γ transcriptional activity, Daidzein also significantly increases PPAR- γ transcriptional activity over a similar range of concentrations at which Daidzein enhanced PPAR- α transcriptional activity, with a maximum increase at 25 μ M^[1]. Daidzein is a soy isoflavone, which upregulates the expression of Abcg1, and it promotes axonal outgrowth in cultured hippocampal neurons via estrogen receptor signaling. Daidzein is a major component of soy with structural similarity to estrogen. It exerts an anti-inflammatory effect, lowers lipid levels, and increases mitochondrial biogenesis. As an activator of nuclear receptor peroxisome proliferator-activated receptors (PPARs), Daidzein enhances transcription of PPARs-dependent genes, including liver X receptors (LXRs, Nr1h gene family in mice). Incubation with different concentrations of Daidzein, from 5 to 100 μ M, increases APOE transcriptional activity^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Treating ApoE KO mice with Daidzein increases Lxr and Abca1 gene expression at 1 month after stroke, showing that the absence of ApoE does not interfere with other cholesterol homeostasis genetic programs. Therefore, the findings suggest that Daidzein-induced ApoE upregulation is a critical component in fostering functional recovery in chronic stroke^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

HEK293T cells are plated on 24-well plates at a cell density of approximately 2.5×10^4 cells/well and are grown to 70-80% confluence. Cells are then transiently transfected with a PPAR- α or PPAR- γ expression plasmid, and a plasmid containing the luciferase gene under the control of three tandem PPAR response elements (PPRE \times 3 TK-luciferase) using an X-treme GENE HP DNA Transfection Reagent. Renilla luciferase control vectors are co-transfected to control for transfection efficiency. After transfection, cells are cultured for another 24 h in medium containing DMSO or various concentrations (6.25, 12.5, 25 μ M) of Daidzein. Cells are lysed, and luciferase activity is measured and expressed as fold induction, that is normalized to the activity of the renilla luciferase control plasmid^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[2]

Mice^[2]

Experiments are performed in 10- to 11-week-old male C57 (C57 bl/6) and ApoE KO (C57 background) mice. For long-term stroke recovery, mice receive Moxifloxacin (100 mg/kg) for 3 d. The prophylactic antibiotic treatment is shown to effectively reduce mortality in an animal model of stroke by attenuating peripheral infection. In addition, saline is subcutaneously administered daily, and hydrogel (Clear H₂O) is given to prevent dehydration. With the implementation of poststroke care (antibiotic regimen, rehydration, and feeding hydrogels with soft diet) during the acute period (<1 week), mice start to regain their body weight by day 5 and continue to recover from stroke. Animals are randomly selected for vehicle or Daidzein treatment. Vehicle or Daidzein (10 mg/kg) is administered subcutaneously within 30 min of reperfusion after confirming the reperfusion of blood flow, daily for 7 d and then every other day up to 1 month.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Rep Med. April 20, 2022.
- J Ethnopharmacol. 2024 Jan 24;117824.
- Mol Neurobiol. 2023 Dec 8.
- Eur J Pharmacol. 2022 Mar 15;919:174805.
- Eur J Pharmacol. 2020 Oct 15;885:173399.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Sakamoto Y1, et al. The Dietary Isoflavone Daidzein Reduces Expression of Pro-Inflammatory Genes through PPAR α / γ and JNK Pathways in Adipocyte and Macrophage Co-Cultures. PLoS One. 2016 Feb 22;11(2):e0149676.
- [2]. Kim E, et al. Daidzein Augments Cholesterol Homeostasis via ApoE to Promote Functional Recovery in Chronic Stroke. J Neurosci. 2015 Nov 11;35(45):15113-26.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA